Patents by Inventor Joseph P. Hammang
Joseph P. Hammang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6294346Abstract: A culture method for determining the effect of a biological agent on multipotent neural stem cell progeny is provided. In the presence of growth factors, multipotent neural stem cells are induced to proliferate in culture. The multipotent neural stem cells may be obtained from normal neural tissue or from a donor afflicted with a disease such as Alzheimer's Disease, Parkinson's Disease or Down's Syndrome. At various stages in the differentiation process of the multipotent neural stem cell progeny, the effects of a biological agent, such as a virus, protein, peptide, amino acid, lipid, carbohydrate, nucleic acid or a drug or pro-drug on cell activity are determined. Additionally, a method of screening the effects of biological agents on a clonal population of neural cells is provided. The technology provides an efficient method for the generation of large numbers of pre- and post-natal neural cells under controlled, defined conditions.Type: GrantFiled: June 7, 1995Date of Patent: September 25, 2001Assignee: Neurospheres Holdings, Ltd.Inventors: Samuel Weiss, Brent Reynolds, Joseph P. Hammang, E. Edward Baetge
-
Patent number: 6264941Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.Type: GrantFiled: January 25, 1999Date of Patent: July 24, 2001Assignee: Neurotech S.A.Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
-
Patent number: 6225448Abstract: This invention provides cells containing recombinant polynucleotides coding for cell surface molecules that, when expressed in the cell, result in rejection of the cell by the host immune system. The invention also provides methods of using such cells, and capsules for delivery of biologically active molecules to a patient.Type: GrantFiled: May 2, 2000Date of Patent: May 1, 2001Assignee: Neurotech S.A.Inventors: Weng Tao, Shou Wong, William F. Hickey, Joseph P. Hammang, E. Edward Baetge
-
Patent number: 6197294Abstract: This invention provides cells containing recombinant polynucleotides coding for cell surface molecules that, when expressed in the cell, result in rejection of the cell by the host immune system. The invention also provides methods of using such cells, and capsules for delivery of biologically active molecules to a patient.Type: GrantFiled: October 26, 1998Date of Patent: March 6, 2001Assignee: Neurotech S.A.Inventors: Weng Tao, Shou Wong, William F. Hickey, Joseph P. Hammang, E. Edward Baetge
-
Patent number: 6071889Abstract: Methods for administering genetic material to dividing neural precursor cell populations in vivo are provided. The genetic material may comprise useful genes for neurotransmitters, growth factors, growth factor receptors, and the like. The genetic material is administered to the brain with one or more growth factors. The growth factors induce proliferation of neural precursor cells, thereby facilitating the incorporation of the genetic material into the cell progeny.Type: GrantFiled: June 7, 1995Date of Patent: June 6, 2000Assignee: NeuroSpheres Holdings Ltd.Inventors: Samuel Weiss, Brent Reynolds, Joseph P. Hammang, E. Edward Baetge
-
Patent number: 6027721Abstract: Methods and devices are provided for gene therapy using encapsulated packaging cell lines to deliver viral particles carrying at least one heterologous gene encoding at least one biologically active molecule.Type: GrantFiled: May 20, 1996Date of Patent: February 22, 2000Assignee: Cytotherapeutics, Inc.Inventors: Joseph P. Hammang, Patrick Aebischer
-
Patent number: 5935849Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.Type: GrantFiled: July 20, 1994Date of Patent: August 10, 1999Assignee: CytoTherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5908623Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.Type: GrantFiled: May 25, 1995Date of Patent: June 1, 1999Assignee: CytoTherapeutics, Inc.Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
-
Patent number: 5904144Abstract: The present invention provides novel devices and methods for continuous, controlled delivery of a biologically active molecule to the eye, either intraocularly or periocularly, to treat ophthalmic disorders. A capsule is surgically placed in the desired location in the eye. The capsule includes cells which produce the biologically active molecule. The capsule also includes a surrounding biocompatible jacket through which the biologically active molecule may diffuse into the eye. This jacket may immunoisolate the encapsulated cells, protecting them from attack by the immune system of the patient.Type: GrantFiled: March 22, 1996Date of Patent: May 18, 1999Assignee: CytoTherapeutics, Inc.Inventors: Joseph P. Hammang, E. Edward Baetge, Peter D. Spear, William G. Tsiaras
-
Patent number: 5858747Abstract: Methods and compositions are provided for controlling cell distribution within an implantable bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the bioartificial organ with extracellular matrix molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination. The bioartificial organ typically has a semipermeable membrane encapsulating a cell-containing core, and is preferably immunoisolatory.Type: GrantFiled: May 23, 1995Date of Patent: January 12, 1999Assignee: CytoTherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5853717Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.Type: GrantFiled: May 23, 1995Date of Patent: December 29, 1998Assignee: CytoTherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5851832Abstract: A method for the in vitro proliferation and differentiation of neural stem cells and stem cell progeny comprising the steps of (a) isolating the cells from a mammal, (b) exposing the cells to a culture medium containing a growth factor, (c) inducing the cells to proliferate, and (d) inducing the cells to differentiate is provided.Type: GrantFiled: June 7, 1995Date of Patent: December 22, 1998Assignee: Neurospheres, Ltd.Inventors: Samuel Weiss, Brent Reynolds, Joseph P. Hammang, E. Edward Baetge
-
Patent number: 5843431Abstract: Methods and compositions are provided for controlling cell distribution within an implantable bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the bioartificial organ with extracellular matrix molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.Type: GrantFiled: May 9, 1995Date of Patent: December 1, 1998Assignee: CytoTherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5840576Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.Type: GrantFiled: May 23, 1995Date of Patent: November 24, 1998Assignee: CytoTherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5833979Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.Type: GrantFiled: May 23, 1995Date of Patent: November 10, 1998Assignee: CytoTherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5795790Abstract: Methods and compositions are provided for controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the bioartificial organ with extracellular matrix molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination.Type: GrantFiled: May 23, 1995Date of Patent: August 18, 1998Assignee: Cytotherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5776747Abstract: This invention relates to methods and compositions of controlling cell distribution within a bioartificial organ by exposing the cells to a treatment that inhibits cell proliferation, promotes cell differentiation, or affects cell attachment to a growth surface within the bioartificial organ. Such treatments include (1) genetically manipulating cells, (2) exposing the cells to a proliferation-inhibiting compound or a differentiation-inducing compound or removing the cells from exposure to a proliferation-stimulating compound or a differentiation-inhibiting compound; exposing the cells to irradiation, and (3) modifying a growth surface of the BAO with ECM molecules, molecules affecting cell proliferation or adhesion, or an inert scaffold, or a combination thereof. These treatments may be used in combination. A particular embodiment is directed to derivatizing or adsorbing polyethylene oxide-poly(dimethylsiloxane) copolymer (PEO-PDMS) onto a surface within the bioartificial organ to inhibit cellular attachment.Type: GrantFiled: May 23, 1995Date of Patent: July 7, 1998Assignee: Cytotherapeutics, Inc.Inventors: Malcolm Schinstine, Molly S. Shoichet, Frank T. Gentile, Joseph P. Hammang, Laura M. Holland, Brian M. Cain, Edward J. Doherty, Shelley R. Winn, Patrick Aebischer
-
Patent number: 5750376Abstract: A method for producing genetically modified neural cells comprises culturing cells derived from embryonic, juvenile, or adult mammalian neural tissue with one or more growth factors that induce multipotent neural stem cells to proliferate and produce multipotent neural stem cell progeny which include more daughter multipotent neural stem cells and undifferentiated progeny that are capable of differentiating into neurons, astrocytes, and oligodendrocytes. The proliferating neural cells can be transfected with exogenous DNA to produce genetically modified neural stem cell progeny. The genetic modification can be for the production of biologically useful proteins such as growth factor products, growth factor receptors, neurotransmitters, neurotransmitter receptors, neuropeptides and neurotransmitter synthesizing genes.Type: GrantFiled: June 7, 1995Date of Patent: May 12, 1998Assignee: NeuroSpheres Holdings Ltd.Inventors: Samuel Weiss, Brent Reynolds, Joseph P. Hammang, E. Edward Baetge
-
Patent number: 5676943Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.Type: GrantFiled: May 25, 1995Date of Patent: October 14, 1997Assignee: CytoTherapeutics, Inc.Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich
-
Patent number: 5656481Abstract: This invention provides improved devices and methods for long-term, stable expression of a biologically active molecule using a biocompatible capsule containing genetically engineered cells for the effective delivery of biologically active molecules to effect or enhance a biological function within a mammalian host. The novel capsules of this invention are biocompatible and are easily retrievable. This invention specifically provides improved methods and compositions which utilize cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down regulation in vivo upon implantation into a mammalian host. Furthermore, the methods of this invention allow for the long-term, stable and efficacious delivery of biologically active molecules from living cells to specific sites within a given mammal.Type: GrantFiled: May 25, 1995Date of Patent: August 12, 1997Assignee: Cyto Therapeutics, Inc.Inventors: Edward E. Baetge, Joseph P. Hammang, Frank T. Gentile, Mark D. Lindner, Shelley R. Winn, Dwaine F. Emerich